Vandetanib for advanced non-small cell lung cancer: A meta-analysis

Chinese Journal of Lung Cancer

Volumn 15, Issue 3, 2012, Pages 172-178

  Tao, Ling ^a   Zhuo, Wenlei ^a   Yang, Fan ^a   Zhu, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Lung neoplasms; Meta analysis; Vandetanib

Indexed keywords

VANDETANIB;

ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; COUGHING; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; TREATMENT RESPONSE; VOMITING;

EID: 84955320188     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2012.03.07     Document Type: Article

References (16)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 2006, 24(14): 2137-2150.
2. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non small cell lung cancer: a review of the current evidence. Chest, 2003, 123(Suppl 1): 137S-146S.
3. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-smallcell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol, 2010, 11(7): 619-626.
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small-cell lung cancer previously treated with platinum-basedchemotherapy. J Clin Oncol, 2000,18(10): 2095-2103.
5. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmall- cell lung cancer previously treated with platinum containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol, 2000, 18(12): 2354-2362.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22(9): 1589-1597.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in Previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
8. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet, 2008, 372(9652): 1809-1818.
9. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non- small-cell lung cancer. J Clin Oncol, 2011, 29(8): 1059-1066.
10. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res, 2002, 62(16): 4645-4655.
11. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res, 2002, 62(24): 7284-7290.
12. Beaudry P, Nilsson M, Rioth M, et al. Potent anti-tumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther, 2008, 7(2): 418-424.
13. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol, 2005, 16(8): 1391-1397.
14. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol, 2006, 1(9): 1002-1009.
15. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol, 2008, 26(33): 5407-5415.
16. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-smallcell lung cancer. J Clin Oncol, 2007, 25(27): 4270-4277.